Гормональная терапия рака предстательной железы как дополнительный фактор кардиоваскулярного риска

Е. С. Бокун, Н. Б. Конончук, С. Л. Поляков, А. И. Ролевич, Л. Н. Суслов, Н. П. Митьковская БГМУ, УЗ «Городская клиническая больница скорой медицинской помощи», ГУ «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н. Н. Александрова»

2015 №4 | Лекции

Аннотация

Список литературы

Скачать полнотекстовую статью

Новообразования предстательной железы занимают второе место среди злокачественных опухолей у мужчин в Республике Беларусь. В терапии рака предстательной железы применяются методики хирургической и медикаментозной кастрации, позволяющие увеличить ожидаемую продолжительность жизни пациентов.

Ключевые слова:

рак предстательной железы, гормональная терапия, кардиоваскулярный риск

Hormonal treatment of prostate cancer as an additional cardiovascular factor

Neoplasms of the prostate occupy the second place among malign tumors in men in Belarus. Surgical and medical castrations are used in the therapy of prostate cancer, allowing to increase the life expectancy of patients.

Keywords

prostate cancer, hormonal treatment, cardiovascular risk

1. Велиев, Е. И. Гормональная терапия рака предстательной железы // Практическая онкология. – 2008. – Т. 9 (2). – С. 98–103.
2. Митьковская, Н. П. Сердце и метаболический риск /Н. П. Митьковская, Е. А. Григоренко, Л. И. Данилова. – Минск: Беларус. наука, 2008. – 277 с.
3. Океанов, А. Е. Статистика онкологических заболеваний в Республике Беларусь (2003–2012) / А. Е. Океанов, П. И. Моисеев, Л. Ф. Левин / под ред. О. Г. Суконко. – Минск: РНПЦ ОМР им. Н. Н. Александрова, 2013. – 373 с.
4. Barkin, J. Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from European Association of Urology Meeting, March 20–24, 2015, Madrid, Spain // The Canadin Journal of Urology. – 2015. – Vol. 22. – P. 7847–7852.
5. Boyanov, M. A. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency / M. A. Boyanov [et al.] // Aging Male. – 2003. – Vol. 6. – P. 1–7.
6. Boxer, R. S. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer / R. S. Boxer [et al.] // Aging Male. – 2005. – Vol. 3–4. – P. 207–212.
7. Braga-Basaria, M. Metabolic syndrome inmen with prostate cancer undergoing longterm androgen-deprivation therapy /M. Braga-Basaria [et al.] // Journal of Clinical Oncology. – 2006. – Vol. 24. – P. 3979–3983.
8. Chen, R. Y. Relative androgen deficiency in relation to obesity and metabolic status in older men / R. Y. Chen [et al.] // Diabetes, Obesity and Metabolism. – 2006. – Vol. 8. – P. 429–435.
9. Efstathiou, J. A. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92–02 / J. A. Efstathiou [et al.] // European Urology. – 2008. – Vol. 54. – P. 816–823.
10. Garg, A. Regional adiposity and insulin resistance // Journal of Clinical Endocrinolgy and Metabolism. – 2004. – Vol. 89, № 9. – P. 4206–4210.
11. Grossman, M. Low testosterone levels are common and associated with insulin resistance in men with diabetes / M. Grossman [et al.] // Journal of Clinical Endocrinolgy and Metabolism. – 2008. – Vol. 93. – P. 1834–1840.
12. Guidelines on Prostate Cancer / European Association of Urology. 2014. – 172 p.
13. Haggstrom, Ch., Stcks T. Prospective Study on Metabolic Factors and Risk of Prostate Cancer. // Cancer. – 2012. –Vol. 118. – P. 6199–6206.
14. Isbam, H. Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks / H. Isbam [et al.] // European Urology. – 2009. – Vol. 55. – P. 62–75.
15. Joanne, M. Androgen-Deprivation Therapy and Metabolic Syndrome in Men With Prostate Cancer / Joanne M. [et al.] // Oncology Nursing Forum. – 2014. – Vol. 41.
16. Keating, N. L. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer / N. L. Keating [et al.] // Journal of Clinical Oncology. – 2006. – Vol. 24. – P. 4448–4456.
17. Keating, N. L. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of Veterans with prostate cancer / N. L. Keating [et al.] // Journal of National Cancer Institution. – 2010. – Vol. 102. – P. 39–46.
18. Lee, H. Changes in bonemineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma / H. Lee [et al.] //Cancer. – 2005. – Vol. 104. – P. 1633–1637.
19. Lughezzani, G. The relationship between obesity and prostate cancer: from genetics to disease treatment and prevention // BMC Medicine. – 2012. – Vol. 10. – P. 109.
20. Muller, M. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men / M. Muller [et al.] // Circulation. – 2004. – Vol. 109. – P. 2074–2079.
21. Nguyen, P. L. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a metaanalysis of randomized trials / P. L. Nguyen [et al.] // JAMA. – 2011. – Vol. 306. – P. 2359–2366.
22. Poppel, H. V. Cardiovascular risk during hormonal treatment in patients with prostate cancer / H. V. Poppel [et al.] // Cancer Management and Research. – 2011. – Vol. 3. – P. 49–55.
23. Saigal, C. S. Androgen deprivation therapy increases cardiovascularmorbidity in men with prostate cancer / C. S. Saigal [et al.] // Cancer. – 2007. – Vol. 110. – P. 1493–1500.
24. Smith, M. R. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer / M. R. Smith [et al.] // Urology. – 2008. – Vol. 71. – P. 318–322.
25. Smith, M. R. Changes in body composition during androgen deprivation therapy for prostate cancer / M. R. Smith [et al.] // Journal of Clinical Endocrinolgy and Metabolism. – 2002. –Vol. 87. – P. 599–603.
26. Smith, M. R. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer / M. R. Smith [et al.] // Urology. – 2004. – Vol. 63. – P. 742–745.
27. Smith, M. R., Lee H., Nathan D. M. Insulin sensitivity during combined androgen blockade for prostate cancer // Journal of Clinical Endocrinolgy and Metabolism. – 2006. – Vol. 91. – P. 1305–1308.
28. Smith, M. R. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer / M. R. Smith [et al.] // New England Journal of Medicine. – 2001. – Vol. 345. – P. 948–955.
29. Stamatiou, K. Is Bilateral Orchiectomy for Metastatic Prostate Cancer Treatment Associated with High Cardiovascular Risc? / K. Stamatiou [et al.] // Aging and Disease. – 2013. –Vol. 4. – P. 381–384.
30. Traish, A. M. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance / A. M. Traish [et al.] // Journal of Andrology. – 2009. – Vol. 30. – P. 23–32.31. Yeap, B. B. Lower testosterone levels predict incident stroke and transient ischemic attack in older men / B. B. Yaep[et al.] // Journal of Clinical Endocrinolgy and Metabolism. – 2009. – Vol. 94. – P. 2353–2359. 32. Wang, J. J. The metabolic syndrome predicts cardiovascular mortality: a 13-yaers follow-up study in elderly non-diabetic Finns / J. J. Wang [et al.] // European Heart Journal. – 2007. – Vol. 12, № 4. – P. 27–38.